Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Huihui Zhang

Fei Liu

Yanlong Liu

Xiquan Zhang

Rui Zhao

Shanchun Wang

Hongjian Wang

Hongmei Gu

Xinlu Li

Ming Zhang

Zhongyuan Hu

Wenjun Geng

Shanliang Zhu

Wenyuan Qian

Yahui Guo

Lei Xing

The present application relates to the field of medicine, and relates to crystals of quinoline derivatives, and in particular, to crystals of a quinoline derivative anhydride and a solvate, as well as a method for preparing the crystals, pharmaceutical compositions containing the crystals, and a use thereof in the field of medicine. The present application further provides a preparation method therefor, which has a high yield, has mild crystallization conditions, is suitable for industrial production, and may better meet the needs of the pharmaceutical industry.

Crystals of quinolone derivatives

Provided is a salt of an Syk inhibitor and a crystalline form thereof, and more specifically, provided are 5-fluoro-1-methyl-3-((5-(4-(oxetan-3-yl)piperazine-1)-yl)pyridin-2-yl)amino)-6-(1H-pyrazol-3-yl)quinoline-2(1H)-ketamine hydrochloride, a crystalline form thereof, a preparation method therefor, a pharmaceutical composition thereof and a use thereof. The hydrochloride of the compound represented by formula I and the crystalline form thereof have good salt-forming properties, high stability and low hygroscopicity, have advantages in terms of physical properties, safety and metabolic stability, and have value in prepared medicines.

Salt of Syk inhibitor and crystalline form thereof

Growing community of inventors

Lianyungang, China

Huihui Zhang